A short look at two next-wave obesity drugs, retatrutide and CagriSema, and where they stand heading into 2026.
Recap by typeshit. Full story at www.polskieradio.pl.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Johns Hopkins researchers report in Annals of Internal Medicine that the pill brought in new patients instead of pulling users away from injectable semaglutide.
7:05
A doctor-led channel runs through ten points to consider before beginning GLP-1 treatment.
Loading…